WallStSmart

Beta Bionics, Inc. Common Stock (BBNX)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 20473% more annual revenue ($20.63B vs $100.25M). GEHC leads profitability with a 10.1% profit margin vs -73.0%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

BBNX

Hold

38

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 7.8
Piotroski: 4/9

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BBNX.

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BBNX3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
57.1%10/10

Revenue surging 57.1% year-over-year

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

BBNX4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$501.96M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-40.3%2/10

ROE of -40.3% — below average capital efficiency

Free Cash FlowQuality
$-10.53M2/10

Negative free cash flow — burning cash

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BBNX

The strongest argument for BBNX centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 57.1% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : BBNX

The primary concerns for BBNX are EPS Growth, Market Cap, Return on Equity.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

BBNX profiles as a hypergrowth stock while GEHC is a value play — different risk/reward profiles.

BBNX is growing revenue faster at 57.1% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (60/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Beta Bionics, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. The company is headquartered in Irvine, California.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?